143 related articles for article (PubMed ID: 23252951)
1. Towards a balanced value business model for personalized medicine: an outlook.
Koelsch C; Przewrocka J; Keeling P
Pharmacogenomics; 2013 Jan; 14(1):89-102. PubMed ID: 23252951
[TBL] [Abstract][Full Text] [Related]
2. Examining the production costs of antiretroviral drugs.
Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
[TBL] [Abstract][Full Text] [Related]
3. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings.
Russo G; McPake B
Health Policy Plan; 2010 Jan; 25(1):70-84. PubMed ID: 19843636
[TBL] [Abstract][Full Text] [Related]
4. The economics of personalized medicine: commercialization as a driver of return on investment.
Keeling P; Roth M; Zietlow T
N Biotechnol; 2012 Sep; 29(6):720-31. PubMed ID: 22713855
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
Lichtenberg FR
Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
[TBL] [Abstract][Full Text] [Related]
6. The impact of generic substitution on price competition in Finland.
Aalto-Setälä V
Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
[TBL] [Abstract][Full Text] [Related]
7. Market uptake of biologic and small-molecule--targeted oncology drugs in Europe.
Obradovic M; Mrhar A; Kos M
Clin Ther; 2009 Dec; 31(12):2940-52. PubMed ID: 20110034
[TBL] [Abstract][Full Text] [Related]
8. Company stock prices before and after public announcements related to oncology drugs.
Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
[TBL] [Abstract][Full Text] [Related]
9. Price regulation and generic competition in the pharmaceutical market.
Dalen DM; Strøm S; Haabeth T
Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing the difference between forecasted and actual drug sales volumes under the price-volume agreement in South Korea.
Park SY; Han E; Kim J; Lee EK
Health Policy; 2016 Aug; 120(8):867-74. PubMed ID: 27346072
[TBL] [Abstract][Full Text] [Related]
11. When medicine becomes a disease.
Arabia; 1986 Mar; 5(55):32-6. PubMed ID: 12340711
[TBL] [Abstract][Full Text] [Related]
12. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
13. [PHARMACEUTICAL INDUSTRY AND PERSONALIZED MEDICINE: A PARADIGM SHIFT IN THE DEVELOPMENT OF NEW DRUGS].
Scheen AJ
Rev Med Liege; 2015; 70(5-6):237-41. PubMed ID: 26285445
[TBL] [Abstract][Full Text] [Related]
14. Personalized medicine: a paradigm for a sustainable pharmaceutical industry?
Chackalamannil S; Desai MC
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):443-5. PubMed ID: 19562640
[TBL] [Abstract][Full Text] [Related]
15. The cost of developing imaging agents for routine clinical use.
Nunn AD
Invest Radiol; 2006 Mar; 41(3):206-12. PubMed ID: 16481902
[TBL] [Abstract][Full Text] [Related]
16. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
17. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
Augurzky B; Göhlmann S; Gress S; Wasem J
Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
[TBL] [Abstract][Full Text] [Related]
18. Priceless goods: how should life-saving drugs be priced?
Maitland I
Bus Ethics Q; 2002 Oct; 12(4):451-80. PubMed ID: 12708456
[TBL] [Abstract][Full Text] [Related]
19. The cocaine and heroin markets in the era of globalisation and drug reduction policies.
Costa Storti C; De Grauwe P
Int J Drug Policy; 2009 Nov; 20(6):488-96. PubMed ID: 19447024
[TBL] [Abstract][Full Text] [Related]
20. Market watch: industry perspectives on personalized medicine.
Zuckerman R; Milne CP
Nat Rev Drug Discov; 2012 Mar; 11(3):178. PubMed ID: 22378258
[No Abstract] [Full Text] [Related]
[Next] [New Search]
